Jeroen van Beek, Ph.D., has served as our Chief Commercial Officer since January 2019. Before joining AlloVir, Dr. van Beek was the Chief Commercial Officer and Senior Vice-President at Tricida in charge of commercial strategy, planning and operations from January 2018 to September 2018. From 2007 to 2017, Dr. van Beek worked at Alexion Pharmaceuticals, most recently as the Vice-President of Global Commercial Operations and Development in charge of the global Soliris® franchise. He was also responsible for the lifecycle management of Soliris® and the commercial development and positioning of Alexion’s portfolio of next-generation complement inhibitors.
During his tenure at Alexion, Dr. van Beek led the launches for Soliris® in two rare diseases: the blood disorder Paroxysmal Nocturnal Hemoglobinuria and the kidney disease atypical Hemolytic Uremic Syndrome.
From 1999 to 2007, Dr. van Beek held positions of increasing commercial responsibility at Pfizer including Marketing Director, Oncology responsible for launching Sutent® for renal cell carcinoma and gastrointestinalstromal tumor.
Dr. van Beek received his B.S. in Chemistry from the University of Virginia, his Ph.D. in Chemistry from Cornell University, and his M.B.A.from the Darden Business School at the University of Virginia.